Pfizer Inc. (PFE) Published Snapshot
Pfizer adds a high-search health-care name, but the first view remains restrained because low multiples alone do not resolve leverage and growth-quality questions.
This page preserves a point-in-time printable snapshot at the report date shown below. It is not the live research workspace. For the current fair value, model signal, filing status, refreshed model output, and private scenario sandbox, return to the company research view.
Current research view reference
Kept here as reference beside the printable snapshot: the current research view now shows a Hold signal with medium confidence as shares are currently being evaluated against an older daily scheduled quote of $26 versus $28 fair value, implying +6.9 upside.
Price vs fair value
+6.8%
Model-implied return
Stale scheduled quote
$26
Fair value
$28
Valuation method stack
Weighted fair value $28
Published method weights
DCF (Base)
$29 | 45%
NTM P/E Multiple
$28 | 35%
EV/EBITDA Cross-check
$27 | 20%
Fundamental snapshot
FY2025
Normalized annual model base
Revenue
-2.5% YoY
$62.0B
Op. margin
+0.9% pts
21.9%
FCF margin
+0.3% pts
11.3%
Published valuation range
Bear / base / bull context
Uses report scenario anchors
DCF (Base)
$29
NTM P/E Multiple
$28
EV/EBITDA Cross-check
$27
Current workspace signal
Hold
Confidence
Medium
Stale scheduled quote
$26
Fair value
$28
+6.9 upside
Reference freshness
Price basis
Stale scheduled quote
Latest daily scheduled quote is past the freshness window. Daily scheduled refresh as of Jun 15, 2026, 9:39 AM UTC. Fresh through Jun 16, 2026, 9:39 AM UTC.
Filing reference
4 filed Jun 16, 2026 | Reporting period Jun 15, 2026
Filing refreshed Jun 17, 2026, 4:07 AM UTC. Fresh through Jun 17, 2026, 4:07 PM UTC.
Fundamentals reference
Live SEC companyfacts currently cover revenue, free cash flow, and net cash / net debt. Reporting period end 2025-12-31.
Fundamentals refreshed 17 Jun 2026, 03:56 UTC. Fresh through 17 Jun 2026, 15:56 UTC.
Thesis scorecard
Growth
WeakThe revenue base is still resetting after pandemic-era demand.
Profitability
ModerateMargins can improve, but mix and reinvestment remain important.
Balance sheet
WeakDebt is a real constraint for the current model.
Valuation
ModerateThe multiple is low, but the model does not treat that as enough on its own.
Execution / Resilience
ModeratePipeline and integration execution need evidence.
Bull / Base / Bear scenarios
Bull case
$34
Normalized support: Growth, margin, and cash-flow trends are mixed versus the upside case.
Base case
$28
Normalized support: Current margin, cash-generation, and balance-sheet profile are mixed.
Bear case
$21
Downside protection: Cash generation and balance-sheet support are mixed in the bear case.
Base-case assumptions
These are the published base-case assumptions behind the note. They are reasoned valuation inputs at the report date, not reported facts.
Revenue CAGR (5Y)
2.5%
+/- 1.0% => +/-$1/sh
Why this level: This is AnalystScope's base-case growth assumption, not a guarantee. It sits below the latest FY model-base revenue pace (2025.0%), so the model does not extend current strength too far into the outer years. Current company context: Pipeline and acquisition integration determine the medium-term growth bridge.
Terminal Growth
1.8%
+/- 0.5% => +/-$1/sh
Why this level: This is AnalystScope's mature long-run growth assumption, not a perpetual hypergrowth claim. At 1.8%, it sits well below the 2.5% five-year revenue CAGR, so the model steps down from the explicit forecast period to a steadier long-run pace. For Pfizer Inc., that means a durable franchise can keep compounding after year five without assuming today's faster growth profile lasts indefinitely.
WACC
8.4%
+/- 0.5% => -$2/sh
Why this level: This is AnalystScope's base-case cost-of-capital judgment, not a precise CAPM output. It reflects the current rates backdrop, equity risk premium, and the company's balance-sheet posture. Leverage and portfolio-reset execution remain central constraints
Operating Margin (Year 5)
23.0%
+/- 100 bps => +/-$1/sh
Why this level: This is AnalystScope's base-case margin view, not a promise of straight-line expansion. It keeps year-five margins close to today's model-base operating margin (21.9%), which implies the current margin structure is broadly durable. Margin input reflects cost actions and mix recovery but keeps pharma reinvestment needs visible.
How to read the assumptions and sensitivities
These are base-case assumptions used to estimate fair value. They are reasonable model inputs, not reported facts.
Each sensitivity line shows the estimated fair-value-per-share change from a small move in that one input while the other inputs stay fixed.
bps means basis points. 100 bps equals 1.00 percentage point.
WACC sensitivity moves in the opposite direction because a higher discount rate lowers present value, while a lower discount rate raises it.
Model base vs reported fundamentals
Side-by-side view of the latest live reported fundamentals versus the current AnalystScope model base used in public valuation and thesis work.
Reported numbers show the latest company print. Model base is the comparable operating base AnalystScope uses for valuation work, which can include standardization, conservative balance-sheet treatment, working-capital cleanup, and through-cycle adjustments when current reported figures do not look durable.
Reported fundamentals source
SEC XBRL companyfacts API
Live SEC companyfacts currently cover revenue, free cash flow, and net cash / net debt. Reporting period end 2025-12-31.
Fundamentals refreshed 17 Jun 2026, 03:56 UTC. Fresh through 17 Jun 2026, 15:56 UTC.
Model-base impact on the thesis
Pfizer is modeled as a low-multiple pharmaceutical reset story where leverage and evidence of portfolio stabilization matter as much as headline valuation.
| Metric | Live reported | Status | Model base | Status |
|---|---|---|---|---|
| Revenue (TTM) | $62.6B | Live reported | $62.0B -2.5% YoY Adjustment: Model revenue smooths the post-pandemic portfolio reset and avoids assuming a sharp immediate rebound. | Model base |
| Operating Margin | Unavailable | Unavailable | 21.9% +87 bps YoY Adjustment: Margin input reflects cost actions and mix recovery but keeps pharma reinvestment needs visible. | Model base |
| FCF (TTM) | $9.1B | Live reported | $7.0B 11.3% margin Adjustment: FCF input normalizes working-capital and integration timing after portfolio moves. | Model base |
| Net Cash / (Debt) | ($62.7B) | Live reported | ($48.0B) Leverage and portfolio-reset execution remain central constraints Adjustment: Balance-sheet treatment keeps leverage central to the rating rather than focusing only on low multiples. | Model base |
Published investment view
The published snapshot remains anchored to a Hold rating, with the latest note event recorded as New. The current workspace now evaluates the stock against $26 versus a base-case fair value of $28, implying +6.9 upside.
Fair value $28 vs. current $26 (+6.9 upside).
Confidence framing
Method agreement / dispersion
Valuation methods are tightly grouped, with implied values ranging from $27 to $29.
Margin strength
Operating margin is 21.9%, with +87 bps vs prior FY.
Balance sheet position
Balance sheet positioning is ($48.0B), with leverage and portfolio-reset execution remain central constraints.
Key drivers
Portfolio stabilization after pandemic-era revenue normalization is the core driver.
Cost actions and mix recovery can support margin repair.
Pipeline and acquisition integration determine the medium-term growth bridge.
Key risks
Revenue reset could last longer than the current base case assumes.
Debt and acquisition integration risk may keep valuation support muted.
Pipeline misses would make the low-multiple case less compelling.
What would change our view
Clear evidence of non-pandemic portfolio growth would improve the setup.
Debt reduction and stronger free cash flow would raise confidence.
Further revenue weakness or integration issues would keep the rating constrained.
Near-term catalysts
Portfolio-growth commentary and pipeline milestones remain key.
Cost-savings progress can affect margin confidence.
Free-cash-flow conversion and debt reduction are important model checks.
What we are watching
Whether core product growth is enough to offset mature and declining franchises.
How quickly leverage begins to move lower.
Whether cost actions improve margins without damaging the growth bridge.
Report archive context
Archive metadata below keeps the published snapshot context visible. Current research-view valuation and quote context stay secondary on this page.
How to read note event vs rating
Note event tells you what changed in the latest published note. Published rating shows the stance after that event.
Both were published Jun 13, 2026.
Report updated
Jun 13, 2026
Coverage status
Active coverage
Latest note event
New
Published Jun 13, 2026
Current published rating
Hold
Published Jun 13, 2026
Analyst note
Watching portfolio stabilization, debt reduction, and pipeline execution before assigning stronger conviction.
What changed in the report
Jun 13, 2026
Added to AnalystScope coverage
Impact: Started coverage with a Hold view on low-multiple support versus leverage and growth-reset risk.
Jun 13, 2026
Initialized normalized annual model base
Impact: Adds a pharma reset case without letting low headline multiples overstate conviction.
Report timeline
Jun 13, 2026
Started coverage with a Hold view on low-multiple support versus leverage and growth-reset risk.